Eli Lilly and Company (SWX:LLY)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 571.23B |
| Revenue (ttm) | 43.32B |
| Net Income (ttm) | 9.82B |
| Shares Out | n/a |
| EPS (ttm) | 10.86 |
| PE Ratio | 58.18 |
| Forward PE | 30.09 |
| Dividend | 4.81 (0.75%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | n/a |
| Average Volume | 5 |
| Open | n/a |
| Previous Close | 645.00 |
| Day's Range | n/a |
| 52-Week Range | 660.00 - 830.00 |
| Beta | 0.33 |
| RSI | 36.04 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circ...
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, wit...
Dividend Roundup: Eli Lilly, Pepsico, Ford, Delta Air Lines, and more
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
Why Eli Lilly is falling plus, what new Costco sales say about the consumer
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More
U.S. equities gained at midday when the U.S. and U.K. struck a new trade deal.
Tesla and Google surge as healthcare sector falters in mixed market
Today's Market Overview The US stock market presents a mixed picture today, with notable performances in the consumer cyclical and communication services sectors. Giants like Tesla and Google are emer...
Lilly announces transitions in executive leadership
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-t...
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...
Healthy Returns: Novo Nordisks Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Eli Lilly Being Investigated on Behalf of Eli Lilly and Company Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violatio...
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
First quarter 2025 total revenue of approximately $53.3 million , which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of...
Eli Lilly Stock Is Sliding Tuesday: What's Going On?
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manu...
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors.
Tech faces turbulence as energy stocks surge: A detailed market analysis
Sector Overview The tech sector is navigating choppy waters today, with major players showing mixed results. Microsoft (MSFT) slipped slightly at -0.34%, while Nvidia (NVDA), a significant semiconduct...
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Mutual Funds Gobble Up Eli Lilly Stock, Ge Vernova And A Wrestling Name
Eli Lilly stock is in a long consolidation pattern and below a critical moving average.
LLY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Eli Lilly and Company investment
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violatio...